Early postnatal lesion of the medial dorsal nucleus leads to loss of dendrites and spines in adult prefrontal cortex.

Research suggests that the medial dorsal nucleus (MD) of the thalamus influences pyramidal cell development in the prefrontal cortex (PFC) in an activity-dependent manner. The MD is reciprocally connected to the PFC. Many psychiatric disorders, such as schizophrenia, affect the PFC, and one of the most consistent findings in schizophrenia is a decrease in volume and neuronal number in the MD. Therefore, understanding the role the MD plays in the development of the PFC is important and may help in understanding the progression of psychiatric disorders that have their root in development. Focusing on the interplay between the MD and the PFC, this study examined the hypothesis that the MD plays a role in the dendritic development of pyramidal cells in the PFC. Unilateral electrolytic lesions of the MD in Long-Evans rat pups were made on postnatal day 4 (P4), and the animals developed to P60. We then examined dendritic morphology by examining MAP2 immunostaining and by using Golgi techniques to determine basilar dendrite number and spine density. Additionally, we examined pyramidal cell density in cingulate area 1 (Cg1), prelimbic region, and dorsolateral anterior cortex, which receive afferents from the MD. Thalamic lesions caused a mean MD volume decrease of 12.4% which led to a significant decrease in MAP2 staining in both superficial and deep layers in all 3 cortical areas. The lesions also caused a significant decrease in spine density and in the number of primary and secondary basilar dendrites on superficial and deep layer pyramidal neurons in all 3 regions. No significant difference was observed in pyramidal cell density in any of the regions or layers, but a nonsignificant increase in cell density was observed in 2 regions. Our data are thus consistent with the hypothesis that the MD plays a role in the development of the PFC and, therefore, may be a good model to begin to examine neurodevelopmental disorders such as autism and schizophrenia.

A comparative study of MAP2 immunostaining in areas 9 and 17 in schizophrenia and Huntington chorea.

Increasing evidence suggests that there may be significant morphological changes in the neuropil of the dorsolateral prefrontal cortex in schizophrenia. A controversial issue surrounding these deficits in the cortical neuropil is the confounding effects of antipsychotic (neuroleptic) medication as well as the question of generality to psychiatric disorders. To begin to address these issues we examined brains from Huntington's patients matched to a cohort of schizophrenics and controls. Many Huntington's patients take neuroleptics similar to schizophrenics; therefore, by comparing the two groups to controls we can begin to determine if neuroleptics play a role in the deficits reported in schizophrenia. Using MAP2 immunohistochemistry and thionin staining eight matched triplets of Huntington, schizophrenia and control, in areas 9 and 17 layers III and V were analyzed. Our results confirmed previous published data showing a schizophrenia-associated decrease in MAP2 in area 9 with no change in area 17. Similarly the Huntington's patients showed no change in area 9 layer III and no change in area 17. There was however, a modest decrease observed in layer V area 9 of the Huntington's patients. Neuron density measurements showed no change in either layer or brain region in any of the diagnostic categories. These observations suggest that antipsychotic medication may not be responsible for some of the morphological changes observed in the neuropil of the PFC in schizophrenia.

Evidence of altered calmodulin immunoreactivity in areas 9 and 32 of schizophrenic prefrontal cortex.

Schizophrenia is a severe neuropsychiatric disorder. Previous studies have implicated the prefrontal cortex (PFC) [Harrison PJ. The neuropathology of schizophrenia a critical review of the data and their interpretation. Brain 1999;122:593-624; Jones LB. Recent cytoarchitectonic changes in the prefrontal cortex of schizophrenics. Frontiers of Bioscience 2001;6:E148-53]. Recent immunocytochemical studies have shown a dramatic decrease in MAP2 and neurogranin [Jones L, Johnson N, Byne W. Alterations in MAP2 staining in area 9 and 32 of schizophrenic prefrontal cortex. Psychiatry Research 2002;114:137-48; Broadbelt K, Pamprasaud A, Jones LB. Evidence of altered neurogranin immunoreactivity in areas 9 and 32 of schizophrenic prefrontal cortex. Schizophrenia Research 2006;87:6-14] a loss of either is suggestive of dendritic lesions [Li GL, Farooque M, Lewen A., Lennmyr F, Holtz A., Olsson Y. MAP2 and neurogranin as markers for dendritic lesions in cns injury an immunohistochemical study in the rat. APMIS 2002;108:98-106.]. Neurogranin is an upstream regulator of calcium and calmodulin [Prichard L, Deloulmes JC, Storm DR. Interactions between Neurogranin and Calmodulin in vivo. Journal of Biological Chemistry 1999;274:7689-94]. A direct action of this pathway is the phosphorylation of MAP2, which is required for microtubule stabilization. Because of the above findings as well as moropholigical alterations [Broadbelt K, Byne W, Jones LB. Evidence for a decrease in primary and secondary basilar dendrites on pyramidal cells in area 32 of schizophrenic prefrontal cortex. Schizophrenia Research 2002;58:75-81] we examined the expression of the active form of calmodulin in layers III and V of areas 9 and 32 in six controls and six schizophrenics matched for age, sex, and postmortem interval. Using area fraction analysis we quantified immunostaining and counted the number of immunopositive pyramidal cells and interneurons as well as immunonegative pyramidal cells. Area fraction analysis showed a significant decrease in immunostaining in area nine layers III (58%) and V (44%), area 32 layers III (51%) and V (32%). We found a significant reduction in the density of immunopositive pyramidal cells in area 9 (11%) layer III, (20%) layer V, area 32 (16%) layer III and (17%) layer V with no difference in immunopositive interneurons. These data suggest a loss of the active form of calmodulin with pyramidal cells being preferentially affected suggesting that the calcium calmodulin dependent pathway may be altered in the pyramidal cells in the PFC.

Evidence of altered neurogranin immunoreactivity in areas 9 and 32 of schizophrenic prefrontal cortex.

Schizophrenia is a complex and poorly understood neuropsychiatric disorder. Much research has begun to implicate the prefrontal cortex in the disease. Using immunocytochemistry we determined if neurogranin, a protein found in dendrites, spines and cell bodies and an upstream regulator of calcium was altered in areas 9 and 32 of schizophrenic prefrontal cortex. We examined its expression in pyramidal cells in layers III and V. Tissues from 7 controls and 7 schizophrenics (from our original MAP2 study, Jones, L., Johnson, N., Byne, W., 2002. Alterations in MAP2 staining in area 9 and 32 of schizophrenic prefrontal cortex. Psych. Res. 114, 137-148) matched for age, sex and postmortem interval were examined. Using area fraction analysis we quantified the immunostaining. Additionally, we counted the number of positively stained pyramidal cells in the same 7 pairs. Neurogranin immunostaining was dramatically reduced in both layers III (72%) and V (50%) in area 9. In area 32 there was a more modest reduction in both layers III (36%) and V (40%). There was no difference in either brain region or layer in the density of positively stained pyramidal cells. These data confirm mounting evidence suggesting dendritic loss in the prefrontal cortex and suggest that the loss of protein does not appear to be due to a change in the number of cells producing the protein but rather in the amount of protein being produced. Additionally, these data suggest that the loss of neurogranin may alter the calcium-calmodulin dependent pathways due to its role as a regulator of calmodulin suggesting a link between structural and functional alterations of the pyramidal cells in the prefrontal cortex.

Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial prefrontal cortex.

A variety of lines of converging evidence implicates the prefrontal cortex (PFC) in schizophrenia. Previous neuroanatomical studies have shown schizophrenia-associated changes in neuron density, soma size and spine number. We recently demonstrated a schizophrenia-associated decrease in microtubule-associated protein 2 (MAP2) immunostaining in laminae III and V of medial prefrontal area 32 and interpreted that finding as suggestive of a loss of dendritic material. We now present data from medial prefrontal area 32 of 11 schizophrenics and 11 comparison subjects. In Golgi-stained material, we describe a significant decrease in the number of both primary (29%) and secondary (46%) basilar dendrites on pyramidal neurons in layer V. Similarly, in layer III there was also a decrease in both primary (17%) and secondary (15%) basilar dendrites. These findings suggest a decrease in synaptic surface area which could lead to aberrant information processing.

Alterations in MAP2 immunocytochemistry in areas 9 and 32 of schizophrenic prefrontal cortex.

A variety of lines of converging evidence implicate the prefrontal cortex (PFC) in schizophrenia. Studies employing Nissl stains have suggested that PFC dendrites may be atrophic in schizophrenia; however, Nissl stains do not reveal dendrites. We employed MAP2 immunocytochemistry, which stains dendrites to examine cortical layers III and V in two areas of the PFC (areas 9 and 32). Occipital cortex (area 17) was examined as a control region. Tissues from seven schizophrenics and seven non-psychiatric controls were examined. Immunostaining was quantitated by area fraction analysis. MAP2 area fraction was decreased in both layers in both regions of PFC, but not in occipital cortex. Area 9 exhibited a 42% reduction in layer V and a 36% reduction in layer III. Area 32 exhibited a 31% reduction in layer V and a 36% reduction in layer III. Neither region exhibited a significant change in the density of pyramidal cells. These data are consistent with the hypothesis of a schizophrenia-associated decrease in dendritic material in the PFC.